Mesenchymal stem cell (MSC)-based cardiac patches are envisioned to be a promising treatment option for patients with myocardial infarction. However, their therapeutic efficacy and duration are hampered due to their limited retention on the epicardium. We engineered a scaffold-free MSC sheet with an inherent ability to migrate into the infarcted myocardium, a strategy enabled by actively establishing a sustained intracellular hypoxic environment through the endocytosis of our FDA-approved ferumoxytol. This iron oxide nanoparticle stabilized hypoxia-induced factor-1α, triggering upregulation of the CXC chemokine receptor and subsequent MSC chemotaxis. Thus, MSCs integrated into 2/3 depth of the left ventricular anterior wall in a rat model of acute myocardial infarction and persisted for at least 28 days. This led to spatiotemporal delivery of paracrine factors by MSCs, enhancing cardiac regeneration and function. Ferumoxytol also facilitated the noninvasive MRI tracking of implanted MSCs. Our approach introduces a strategy for mobilizing MSC migration, holding promise for rapid clinical translation in myocardial infarction treatment.
Keyphrases
- left ventricular
- acute myocardial infarction
- mesenchymal stem cells
- heart failure
- hypertrophic cardiomyopathy
- umbilical cord
- iron oxide
- mitral valve
- cardiac resynchronization therapy
- aortic stenosis
- magnetic resonance imaging
- bone marrow
- percutaneous coronary intervention
- combination therapy
- machine learning
- atrial fibrillation
- poor prognosis
- acute coronary syndrome
- magnetic resonance
- big data
- transcatheter aortic valve replacement
- aortic valve
- reactive oxygen species
- ejection fraction
- loop mediated isothermal amplification
- drug administration